RxDoctor Payments Data

Alvaro Garcia, MD

Family Medicine · Houston, TXNPI 1932103744

Payments from drug & device makers

$843in general payments, 2019–2025

Across 48 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$251
  • Amarin Pharma, Inc.$210
  • Sanofi-aventis U.S. LLC$122
  • Johnson & Johnson$50
  • Lilly USA, LLC$42
  • Novo Nordisk$40
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$71385%
  • Education$13015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$843 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$12,025
Medicare patients
38
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Soliqua 100-33Insulin Glargine/Lixisenatide69$89,076
EliquisApixaban64$86,579
JanuviaSitagliptin Phosphate59$83,204
BiktarvyBictegrav/Emtricit/Tenofov Ala16$73,048
OzempicSemaglutide45$46,939
JardianceEmpagliflozin25$46,380
TrulicityDulaglutide29$44,661
TradjentaLinagliptin27$42,250
LinzessLinaclotide23$34,714
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$26,185
MyrbetriqMirabegron18$26,060
VascepaIcosapent Ethyl27$25,335
FarxigaDapagliflozin Propanediol20$25,143
MounjaroTirzepatide11$13,016
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen241$11,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCSoliqua 100-33$122$89,07669 claims
PfizerEliquis$17$86,57964 claims
Lilly USA, LLCTrulicity, Mounjaro$42$57,67740 claims
Novo NordiskOzempic$40$46,93945 claims
GSKTrelegy Ellipta$18$26,18516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →